CTIC - シ―ティ―アイ・バイオファ―マ (CTI BioPharma Corp.) シ―ティ―アイ・バイオファ―マ

 CTICのチャート


 CTICの企業情報

symbol CTIC
会社名 CTI BioPharma Corp (シ―ティ―アイ・バイオファ―マ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 CTIバイオファーマ(CTI BioPharma Corp. )(旧称:Cell Therapeutics Inc.)は癌を治療する毒性の少ない方法の取得・開発・商品化に焦点を当てるバイオ医薬品会社。同社は満たされていない医療ニーズのある血液関連癌向けの治療に力を集中する。同社は主に再発乗算または難治性の積極的な非ホジキンリンパ腫(NHL)のために、欧州連合でPIXUVRI(ピクサントロン)の商品化に従事する他、骨髄線維症の治療用pacritinibの第三相臨床試験を実行する。PIXUVRIは新規アザ・アントラセンジオン誘導体であり、構造的にアントラサイクリン及びアントラセンジオンに関連するが、心毒性作用の同じレベルに関連すると表示されない。   シ―ティ―アイ・バイオファ―マは、米国のバイオ医薬品会社。癌治療法の取得、開発、商業化に従事する。欧州地方で非ホジキンリンパ腫治療の「PIXUVRI(ピクサントロン)」を商品化することに焦点を当てる。血液関連癌のスペクトルをカバ―する新たな治療標的を当てるほか癌と共に生きる人々のための治療選択肢の開発も展開する。   CTI BioPharma Corp. is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. The company concentrates its efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, we are focused on evaluating pacritinib, our sole product candidate currently in active late-stage development, for the treatment of adult patients with myelofibrosis. In addition, the company has recently started developing pacritinib for use in hospitalized patients with severe COVID-19, in response to the COVID-19 pandemic. The company's headquartered in Seattle, Washington.
本社所在地 3101 Western Avenue Suite 600 Seattle WA 98121 USA
代表者氏名
代表者役職名
電話番号 +1 206-282-7100
設立年月日 33482
市場名 NASDAQ Small Cap
ipoyear 1997年
従業員数 149人
url www.celltherapeutics.com
nasdaq_url https://www.nasdaq.com/symbol/ctic
adr_tso
EBITDA EBITDA(百万ドル) -43.17000
終値(lastsale) 2.05
時価総額(marketcap) 118877294.2
時価総額 時価総額(百万ドル) 118.87730
売上高 売上高(百万ドル) 13.25700
企業価値(EV) 企業価値(EV)(百万ドル) 40.31630
当期純利益 当期純利益(百万ドル) -41.67700
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 CTI BioPharma Corp revenues decreased 52% to $11.1M. Net loss applicable to common stockholders decreased 18% to $15.4M. Revenues reflect License and contract revenue decrease of 49% to $11.1M Product sales net decrease from $1M to $0K. Lower net loss reflects Other selling general decrease of 47% to $8.4M (expense) Other non-operating income (expense) increase from $30K (expense) to $4.7M (income).

 CTICのテクニカル分析


 CTICのニュース

   Must-See Earnings Estimates NASDAQ:RMBL NASDAQ:CALA NASDAQ:CTIC NASDAQ:URGN and #Covid-19 (#Coronavirus) impact  2021/03/21 02:58:00 Stock Market Daily
Earnings, Analyst opinion and estimate and latest Covid-19 (Coronavirus) impact on these hot stocks to invest
   CTI BioPharma (NASDAQ:CTIC) Announces Quarterly Earnings Results  2021/03/19 11:28:41 Transcript Daily
CTI BioPharma (NASDAQ:CTIC) released its quarterly earnings results on Tuesday. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.16) by ($0.04), MarketWatch Earnings reports. Shares of NASDAQ CTIC opened at $3.27 on Friday. The firm’s 50-day moving average price is $3.32 and its 200-day moving […]
   CTI BioPharma (NASDAQ:CTIC) Releases Earnings Results, Misses Expectations By $0.04 EPS  2021/03/19 04:29:29 Daily Political
CTI BioPharma (NASDAQ:CTIC) issued its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.04), MarketWatch Earnings reports. Shares of NASDAQ CTIC opened at $3.27 on Friday. The stock has a market cap of $246.79 million, a P/E ratio of -4.81 and a […]
   CTI BioPharma Reports Fourth Quarter and Full Year 2020 Financial Results  2021/03/17 20:05:00 PR Newswire
SEATTLE, March 17, 2021 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today reported its financial results for the fourth quarter and full year ended December 31, 2020. "This past quarter, CTI has executed on the critical clinical, regulatory and commercial activities that will allow…
   CTI BioPharma to Present at the Cowen 41st Annual Health Care Conference on Thursday, Mar. 4  2021/02/25 12:00:00 PR Newswire
SEATTLE, Feb. 25, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that management will provide a corporate overview at the Cowen 41st Annual Health Care Conference at 12:10 p.m. EST. The conference will be held in a virtual meeting format. Presentation details:…
   Must-See Earnings Estimates NASDAQ:RMBL NASDAQ:CALA NASDAQ:CTIC NASDAQ:URGN and #Covid-19 (#Coronavirus) impact  2021/03/21 02:58:00 Stock Market Daily
Earnings, Analyst opinion and estimate and latest Covid-19 (Coronavirus) impact on these hot stocks to invest
   CTI BioPharma (NASDAQ:CTIC) Announces Quarterly Earnings Results  2021/03/19 11:28:41 Transcript Daily
CTI BioPharma (NASDAQ:CTIC) released its quarterly earnings results on Tuesday. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.16) by ($0.04), MarketWatch Earnings reports. Shares of NASDAQ CTIC opened at $3.27 on Friday. The firm’s 50-day moving average price is $3.32 and its 200-day moving […]
   CTI BioPharma (NASDAQ:CTIC) Releases Earnings Results, Misses Expectations By $0.04 EPS  2021/03/19 04:29:29 Daily Political
CTI BioPharma (NASDAQ:CTIC) issued its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.04), MarketWatch Earnings reports. Shares of NASDAQ CTIC opened at $3.27 on Friday. The stock has a market cap of $246.79 million, a P/E ratio of -4.81 and a […]
   CTI BioPharma Reports Fourth Quarter and Full Year 2020 Financial Results  2021/03/17 20:05:00 PR Newswire
SEATTLE, March 17, 2021 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today reported its financial results for the fourth quarter and full year ended December 31, 2020. "This past quarter, CTI has executed on the critical clinical, regulatory and commercial activities that will allow…
   CTI BioPharma to Present at the Cowen 41st Annual Health Care Conference on Thursday, Mar. 4  2021/02/25 12:00:00 PR Newswire
SEATTLE, Feb. 25, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that management will provide a corporate overview at the Cowen 41st Annual Health Care Conference at 12:10 p.m. EST. The conference will be held in a virtual meeting format. Presentation details:…
   CTI BioPharma to Present at The JMP Securities Hematology Summit on Tuesday, Dec. 15  2020/12/08 12:00:00 PR Newswire
SEATTLE, Dec. 8, 2020 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that management will provide a corporate overview at The JMP Securities Hematology Summit at 3:00 p.m. EST. The conference will be held in a virtual meeting format. Presentation details: Event: The…
   CTI BioPharma Reports Third Quarter 2020 Financial Results  2020/11/10 21:05:00 PR Newswire
SEATTLE, Nov. 10, 2020 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today reported its financial results for the third quarter and nine months ended September 30, 2020. "This past quarter we made significant progress in our pacritinib development program. We recently announced the…
   CTI BioPharma to Report Third Quarter 2020 Financial Results on November 10, 2020  2020/11/02 21:05:00 PR Newswire
SEATTLE, Nov. 2, 2020 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management plans to report its third quarter 2020 financial results on Tuesday, November 10, 2020, after the close of the U.S. financial markets. Following the announcement,…
   CTI BioPharma (NASDAQ:CTIC) Coverage Initiated by Analysts at Brookline Capital Management  2020/10/24 12:38:46 Transcript Daily
Brookline Capital Management began coverage on shares of CTI BioPharma (NASDAQ:CTIC) in a research note issued to investors on Friday, The Fly reports. The firm issued a buy rating and a $7.00 price target on the biopharmaceutical company’s stock. Several other research analysts have also recently weighed in on the company. Lake Street Capital restated […]
   CTI BioPharma Initiates Rolling Submission of New Drug Application (NDA) for Pacritinib in Myelofibrosis Patients with Severe Thrombocytopenia  2020/10/13 11:00:00 PR Newswire
SEATTLE, Oct. 13, 2020 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced that it has commenced a rolling New Drug Application (NDA) submission to the U.S. Food and Drug Administration ("FDA" or "the Agency") seeking approval of pacritinib as a treatment for myelofibrosis…

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 シ―ティ―アイ・バイオファ―マ CTIC CTI BioPharma Corp.)

 twitter  (公式ツイッターやCEOツイッターなど)